Table 3.

Cardiac remodelling echocardiographic, biochemical, and clinical measurements among patients with low vs. medium/high dose of sacubitril–valsartan at follow‐up

	Low dose of sacubitril–valsartan (N = 38)			Medium/high dose of sacubitril–valsartan (N = 25)
	Before sacubitril–valsartan	After sacubitril–valsartan	P value	Before sacubitril–valsartan	After sacubitril–valsartan	P value
LVEF (%)	32 [26.5; 35]	41.5 [32; 58.5]	< 0.001	35 [29.5; 38.5]	45 [37; 52]	<0.001
Left ventricle end‐diastolic volume (mL)	147 [122; 183]	134 [108; 174]	0.048	142 [115; 184]	125 [106; 152]	0.046
Left ventricle end‐systolic volume (mL)	96 [75; 132]	79 [56; 112]	0.001	92 [71; 127.5]	70 [49.5; 94]	0.006
NT‐proBNP (pg/mL)	1552 [838; 6460]	946 [320; 2658]	0.009	1490 [492; 2245]	590 [348; 1011]	0.027
NYHA functional class	2.3 ± 0.7	1.6 ± 0.6	<0.001	2.1 ± 0.7	1.6 ± 0.6	0.001

LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association.

Values are median [inter‐quartile range].